DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pharmacokinetic of Everolimus and Atorvastatin Co-administration

Information source: Chulalongkorn University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Difference of 12-hour AUC

Intervention: Atorvastatin 20 mg (Drug); Everolimus (Drug)

Phase: N/A

Status: Completed

Sponsored by: Chulalongkorn University

Official(s) and/or principal investigator(s):
Anocha Wanitchanont, MD., Principal Investigator, Affiliation: Chulalongkorn University

Summary

Hypothesis : In renal transplantation recipient who received immunosuppressive drug "certican" and have hypercholesterolemia will get lipid lower drug-HMG Co-A reductase inhibitors. Because atorvastatin and everolimus have metabolism via Cytochrome P450 subfamily 3A4 both, so investigator made the hypothesis that when patients received everolimus with atorvastatin will change area under the time concentration curve of everolimus.

Clinical Details

Official title: Drug Interaction and Pharmacokinetic Assessment of Everolimus When Coadministered With Atorvastatin in Renal Transplantation Recipient

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome: 12-hour area under the time concentration curve of everolimus

Secondary outcome:

Renal function

Liver function test

Lipid profile

Rhabdomyolysis

Detailed description: Population : Thai postrenal transplantation recipient who received everolimus and have hypercholesterolemia in posttransplantation clinic at Faculty of Medicine, Chulalongkorn University. Study Design : Experimental study, Two-sample crossover study Sample size calculation :N = 18 Primary outcome : 12-hour area under the time concentration curve of everolimus Secondary outcome : renal function (serum creatinine, creatinine clearance) Method : 1. Patients will random to everolimus or everolimus with atorvastatin 20 mg arm for 1 month. 2. Take blood sample for everolimus concentration at time 0,0. 5, 1, 1. 5, 2, 2. 5, 4, 6, 8, 12 hour 3. After first blood sample, patients will received everolimus only for 1 month (wash out period) 4. Patients will switch to another arm eg. patient who had received everolimus will switch to everolimus with atorvastatin 20 mg for 1 month 5. Take blood sample for everolimus concentration at time 0,0. 5, 1, 1. 5, 2, 2. 5, 4, 6, 8, 12 hour 6. Everolimus level will analyse for 12-hour AUC of everolimus.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Post renal transplantation recipient who received immunosuppressive drug Everolimus

and has hypercholesterolemia

- Co everolimus level within 3-12 ng/mL

- Informed consent

- Patient can follow research methodology

Exclusion Criteria:

- Patient don't want to participate in the study

- Post renal transplantation recipient who have normal lipid profile

Locations and Contacts

King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand
Additional Information

Related publications:

Kovarik JM, Hartmann S, Hubert M, Berthier S, Schneider W, Rosenkranz B, Rordorf C. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol. 2002 Feb;42(2):222-8.

Starting date: September 2012
Last updated: February 7, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017